Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

Summary

To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) for patients with hepatocellular carcinoma and microvascular invasion (MVI) after hepatectomy.

Timeline

Start

2024-06-01

Primary completion

2025-06-30

Completion

2026-11-30

Drugs

Indications